| 摘要 |
<p>#CMT# #/CMT# Use of N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6 dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea (I) and its hydrates, salts or solvates, for the preparation of medicament to treat leukemia and myeloids leukemia, is claimed. #CMT#ACTIVITY : #/CMT# Cytostatic. The anti-tumor activity of (I) was tested in severe combined immunodeficient mice CB-17. The result showed that (I) exhibited tumor mass reduction of 80%. #CMT#MECHANISM OF ACTION : #/CMT# None given. #CMT#USE : #/CMT# (I) is useful to treat acute myeloid leukemia and chronic myelogenous leukemia (claimed). #CMT#ADVANTAGE : #/CMT# (I) provides an improved treatment for leukemia. #CMT#ADMINISTRATION : #/CMT# Administration of (I) is intravenous or oral (claimed). No dosage details given.</p> |
